Alignment Healthcare (ALHC) COO granted 87,719 restricted stock units vesting through 2029
Alignment Healthcare's Chief Operations Officer, Shane J. Hochradel, was granted 87,719 restricted stock units (RSUs) that will vest in approximately equal installments on March 13, 2027, 2028, and 2029. This award is compensation-related and contingent upon his continued service to the company. Following this grant, Hochradel's reported holdings from this award total 87,719 units.
Alignment Healthcare (ALHC) Is Up 10.7% After Earnings Beat, Faster Growth And Higher Star Ratings
Alignment Healthcare (ALHC) reported a strong quarter with a 33.3% rise in revenue, increased earnings per share, and significant membership growth. The company also secured higher Star Ratings for 2026, improving its perceived quality and financial outlook despite softer near-term EBITDA guidance. Analysts have sharply raised full-year earnings estimates, affirming the company's potential for durable profitability through its tech-enabled Medicare Advantage model.
Alignment Healthcare Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
An insider at Alignment Healthcare recently sold shares valued at $600,000, as reported in a new SEC filing. This transaction indicates a significant divestment by a company insider. The details of the sale are publicly available through the Securities and Exchange Commission filing.
Alignment Healthcare Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
An insider at Alignment Healthcare, Inc. (ALHC) recently sold shares totalling $600,000, as reported in a new SEC filing. This transaction occurred on July 1, 2026, and follows several other insider share sales from the company in recent weeks. Alignment Healthcare specializes in Medicare Advantage Plans and aims to improve healthcare for seniors through its consumer-centric platform.
Alignment Healthcare (ALHC) EVP Konowiecki sells 25,000 shares under 10b5-1 plan
Joseph S. Konowiecki, EVP of Corporate Affairs and a director at Alignment Healthcare (ALHC), sold 25,000 shares of common stock at $24.00 per share. This transaction, totaling $600,000, was conducted under a Rule 10b5-1 trading plan adopted on March 4, 2026. Following the sale, Konowiecki still directly holds 1,103,816 shares, indicating the sale represents a small portion of his overall stake.
ALHC (NASDAQ) director reports three June 2026 sales totaling 75,000 shares
Alignment Healthcare, Inc. (ALHC) filed a Form 144, disclosing proposed and recent sales of its common stock. The filing details 75,000 shares originating from a stock bonus and reports three sales by Joseph Konowiecki, each for 25,000 shares, occurring on June 11, June 18, and June 26, 2026, with gross amounts of $525,000, $550,000, and $600,000, respectively. This transparency from the SEC filing helps inform the market about significant insider transactions.
Vice Chairman of Alignment Healthcare Sells 25,000 Shares. Does This Mean Sell ALHC?
Joseph S. Konowiecki, Vice Chairman of Alignment Healthcare, sold 25,000 shares for $575,000 on June 26, 2026. This sale aligns with his typical transaction patterns and represents a 2.2% reduction in his direct holdings. While the company's stock has seen a significant 66.14% return over the past year, insider sales like this, even when part of a trading plan, are often viewed as a slight bearish signal by investors, though studies show such sales are not always predictive of price declines.
Alignment Healthcare stock hits 52-week high at 23.89 USD By Investing.com
Alignment Healthcare (ALHC) stock reached a new 52-week high of $23.89, currently trading at $23.91 with a market capitalization of $4.91 billion, reflecting a 67.14% increase over the past year. Despite this strong performance and 41.81% revenue growth, InvestingPro analysis suggests the stock is overvalued. The company recently beat Q1 2026 earnings expectations and announced CEO John Kao will also become Chairman of the Board.
Enterprise value to EBIT forward of Alignment Healthcare, Inc. – NASDAQ:ALHC
This article provides financial information for Alignment Healthcare, Inc. (NASDAQ: ALHC), specifically focusing on its enterprise value to EBIT forward metric. It indicates that the company is listed on the Nasdaq Stock Market and that the market was closed at the time of publication, with no trades occurring. The content seems to be a financial data point from TradingView, possibly generated from FactSet data.
Alignment Healthcare: A 33% Grower Worth Owning At 48x Forward Earnings, Just Not Yet
Alignment Healthcare (ALHC) recently achieved profitability, growing revenue by 33% and expanding margins, leading to raised full-year guidance and positive analyst revisions. Despite strong operational performance, the stock trades at a premium valuation of 48.8x forward earnings and 28.6x forward EBITDA compared to its peers. Therefore, while a promising long-term prospect, a "Hold" rating is recommended given the current valuation, with a fair value target near $20-22 against a current price of $23, suggesting a more favorable entry point may arise due to its history of sharp drawdowns.
Price to book forward of Alignment Healthcare, Inc. – NASDAQ:ALHC
This article provides financial data for Alignment Healthcare, Inc. (NASDAQ: ALHC), specifically focusing on its Price to Book Forward metric. The content highlights the company's financials within the health services and managed health care sector, as presented on TradingView. It also mentions data sources like ICE Data Services and FactSet.
Price to sales forward of Alignment Healthcare, Inc. – NASDAQ:ALHC
This article provides the "Price to sales forward" value for Alignment Healthcare, Inc. (NASDAQ: ALHC) and indicates that the market was closed with no trades at the time of publication. It lists various data providers for market and reference data, along with copyright information.
Alignment healthcare EVP sells $575,000 in stock By Investing.com
Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare (NASDAQ:ALHC), sold 25,000 shares for $575,000. This sale, conducted under a Rule 10b5-1 plan, occurred as the stock neared its 52-week high after a 65% annual gain, though InvestingPro analysis suggests it is overvalued. The company recently surpassed Q1 2026 earnings expectations and announced leadership changes.
Alignment Healthcare Insider Sold Shares Worth $575,000, According to a Recent SEC Filing
An insider at Alignment Healthcare recently sold shares valued at $575,000, as detailed in a new SEC filing. This marks another significant insider sale for the company, following previous transactions of $550,000 and over $6 million in earlier June. Alignment Healthcare, Inc. provides consumer-centric Medicare Advantage Plans and has recently strengthened its leadership team and presented at major healthcare conferences.
Alignment Healthcare Inc (ALHC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alignment Healthcare Inc (ALHC), detailing its current price momentum score of 9.74 and its ranking within the Healthcare Providers & Services industry. It highlights the stock's trading range between resistance at $26.91 and support at $16.26, suggesting suitability for range-bound swing trading. The analysis includes a summary of technical indicators and moving averages, largely pointing to a "Buy" signal for ALHC.
Alignment healthcare EVP sells $575,000 in stock
Joseph S. Konowiecki, Executive Vice President of Corporate Affairs at Alignment Healthcare (NASDAQ:ALHC), sold 25,000 shares worth $575,000. This sale occurred on June 26, 2026, under a Rule 10b5-1 trading plan and leaves him with over 1.1 million shares. The stock is currently trading near its 52-week high after a 65% gain but is considered overvalued by InvestingPro.
Alignment Healthcare Insider Sold Shares Worth $575,000, According to a Recent SEC Filing
This article reports on an insider at Alignment Healthcare selling shares valued at $575,000. This information comes from a recent SEC filing. The sale indicates significant insider activity at the company.
Alignment healthcare EVP sells $575,000 in stock By Investing.com
Joseph S. Konowiecki, Executive Vice President of Corporate Affairs at Alignment Healthcare, Inc., sold 25,000 shares of the company's common stock for $575,000. This sale occurred on June 26, 2026, when the stock was trading near its 52-week high after a 65% gain, though InvestingPro analysis suggests it is overvalued. The transaction was conducted under a Rule 10b5-1 trading plan, and Konowiecki still holds over a million shares.
Alignment Healthcare (ALHC) EVP sells 25K shares under pre-set 10b5-1 plan
Joseph S. Konowiecki, EVP of Corporate Affairs and a director at Alignment Healthcare (ALHC), reported an open-market sale of 25,000 shares of Common Stock at $23.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. Following the sale, Konowiecki directly owns 1,128,816 shares, indicating the transaction represents a small portion of his total holdings.
ALHC (NASDAQ) director notifies sale of 25,000 shares on 06/11 and 06/18/2026
An insider at Alignment Healthcare, Inc. (ALHC), Joseph Konowiecki, has filed Form 144 to report two planned sales of common stock. Each sale notice is for 25,000 shares, with dates of 06/11/2026 and 06/18/2026. Merrill Lynch is listed as the broker for these transactions.
Alignment Healthcare, Inc. Actuals & Estimates (BOATS:ALHC)
This article provides an overview of Alignment Healthcare, Inc. (ALHC) financials, actuals, and analyst estimates. Key information includes historical stock prices, upcoming earnings dates, recent earnings per share and revenue figures, net income, lack of dividend payments, and employee count. It also states the maximum and minimum price estimates from analysts for ALHC.
Alignment Healthcare Inc (ALHC) Financial Health: Profitability & Balance Sheet Analysis
Alignment Healthcare Inc (ALHC) has a current financial score of 9.11, placing it highly within the Healthcare Providers & Services industry. The company exhibits robust financial health and high operating efficiency, with a recent quarterly revenue increase of 33.26% year-over-year and a net profit increase of 225.26% year-over-year. This analysis highlights its strong profitability and balance sheet performance.
Alignment Healthcare Stock Watch: Why This $550,000 Insider Sale Shouldn't Spook Investors
Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare, sold 25,000 shares worth $550,000 as part of a pre-arranged trading plan. This sale represented only 2.12% of his direct holdings, and he retains over 1.15 million shares, indicating no significant loss of confidence. The company is demonstrating strong financial performance, with notable revenue and membership growth, and raised its full-year guidance.
Alignment Healthcare (ALHC) Stock Could Be 12.3% Undervalued After Earnings Beat
Alignment Healthcare (ALHC) recently reported stronger-than-expected quarterly earnings and announced leadership changes, including CEO John Kao becoming Chairman. The stock has seen significant returns over the past year and analysts believe it is still undervalued by approximately 12.3%, trading below its fair value of $24.92. This valuation is based on expectations of increased growth, improved margins, and higher future earnings multiples, though potential risks from Medicare Advantage policy changes and member growth need to be considered.
Alignment Healthcare (ALHC) EVP sells 25K shares under 10b5-1 plan
Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare (ALHC), sold 25,000 shares of the company's common stock at $22.00 per share in an open-market transaction. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. Following the transaction, Konowiecki directly holds 1,153,816 shares of Alignment Healthcare.
Joseph Konowiecki proposes sale of 25,000 ALHC shares (NASDAQ: ALHC)
Joseph Konowiecki has filed a Form 144 notice proposing the sale of 25,000 shares of Alignment Healthcare, Inc. (ALHC) common stock, valued at $525,000. This proposed transaction is scheduled for June 11, 2026, and follows a stock bonus of 75,000 shares vested in 2014. As of June 18, 2026, the company has 550,000 shares outstanding.
Alignment Healthcare And 2 Other Stocks That May Be Trading Below Estimated Value
This article identifies three U.S. stocks—Alignment Healthcare (ALHC), Ouster (OUST), and Tutor Perini (TPC)—that are currently trading below their estimated fair values based on future cash flow. It provides a brief overview of each company's operations, market capitalization, and the estimated discount to fair value, highlighting their growth prospects despite some concerns like share price volatility or insider selling. The piece suggests these companies offer potential opportunities for investors seeking undervalued stocks in a robust market.
Alignment Healthcare And 2 Other Stocks That May Be Trading Below Estimated Value
This article highlights three US stocks—Alignment Healthcare (ALHC), Ouster (OUST), and Tutor Perini (TPC)—that are identified as potentially undervalued based on cash flow analysis. It provides an overview of each company, their estimated discount to fair value, revenue and earnings growth forecasts, and recent developments, suggesting these stocks could offer growth opportunities for investors.
Alignment Healthcare Inc (ALHC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Alignment Healthcare Inc (ALHC), highlighting its current earnings forecast score of 8.71 and an average price target of $21.00 from 14 analysts. It details expected revenue for the next quarter at $1.31 billion and an anticipated EPS of $0.13. The analysis suggests a "Buy" trend based on analyst ratings, while cautioning that it is not trading advice and investors should perform their own analysis.
3 Reasons We Love Alignment Healthcare (ALHC)
Alignment Healthcare (ALHC) is highlighted for its strong financial performance despite recent stock underperformance. The company, which provides Medicare Advantage plans, has shown significant revenue growth, a positive shift in EPS, and an increasing free cash flow margin. The article suggests that these factors indicate ALHC is a high-quality business, potentially making it an attractive investment opportunity.
3 Reasons We Love Alignment Healthcare (ALHC)
Alignment Healthcare (ALHC) is highlighted as an attractive investment despite recent stock underperformance. The article cites three key reasons: strong revenue growth with a 33.6% CAGR over five years, positive long-term EPS growth, and an expanding free cash flow margin, indicating improved financial health and a less capital-intensive business model. These factors suggest a promising future for the company, which focuses on Medicare Advantage plans for seniors.
3 Reasons We Love Alignment Healthcare (ALHC)
Alignment Healthcare (ALHC) exhibits strong investment appeal due to its significant revenue growth, outstanding long-term EPS improvement, and increasing free cash flow margin. Despite a recent underperformance compared to the S&P 500, the company's robust financials and customer-centric healthcare model suggest it is a high-quality business with potential for future gains. Investors can access a free, in-depth research report to further evaluate ALHC's prospects.
Alignment Healthcare (ALHC) president sells 30,000 shares under Rule 10b5-1 plan
Alignment Healthcare (ALHC) President Dawn Christine Maroney sold 30,000 shares of common stock at a weighted-average price of $19.5475 per share, totaling $586,425. This transaction was conducted under a Rule 10b5-1 trading plan adopted on May 22, 2025. Following the sale, Maroney directly holds 947,313 shares, maintaining a significant ownership stake in the company.
Alignment healthcare chief medical officer Kim sells $713,947 in common stock
Kim Hyong, Chief Medical Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 35,951 shares of common stock for approximately $713,947 on June 12, 2026, under a pre-arranged trading plan. This sale occurred amidst a 28.86% stock surge over the past week, bringing the current price to $19.78. Following the transaction, Kim still directly owns 331,750 shares of the company.
Alignment healthcare chief medical officer Kim sells $713,947 in common stock
Kim Hyong, Chief Medical Officer of Alignment Healthcare, sold 35,951 shares of the company's common stock for approximately $713,947. This sale, executed under a Rule 10b5-1 trading plan, occurred after a significant 28.86% surge in the stock's price over the past week. Following the transaction, Mr. Kim directly owns 331,750 shares of Alignment Healthcare.
Alignment Healthcare (NASDAQ: ALHC) CMO sells 35,951 shares
Alignment Healthcare's Chief Medical Officer, Hyong Kim, sold 35,951 shares of common stock on June 12, 2026, at a weighted-average price of $19.8589 per share. This sale was conducted under a pre-arranged Rule 10b5-1 plan adopted in March 2026. Following the transaction, Kim directly holds 331,750 shares of ALHC common stock.
KeyBanc reiterates Overweight on Alignment Healthcare stock at $28 By Investing.com
KeyBanc has reiterated an Overweight rating on Alignment Healthcare (NASDAQ:ALHC) with a $28 price target, despite recent stock volatility. The firm attributes the pressure to market rotation towards larger healthcare insurers and considers bearish arguments about 2026 guidance and medical loss ratio overblown, citing solid fundamentals and attractive valuation. The company also recently reported strong Q1 2026 earnings, surpassing analyst expectations, and announced leadership changes with founder John Kao becoming Chairman.
Alignment Healthcare Insider Sold Shares Worth $6,066,621, According to a Recent SEC Filing
An insider at Alignment Healthcare, Inc. recently sold shares valued at $6,066,621, as reported in a new SEC filing. This transaction was published on June 12, 2026, at 04:16 pm EDT. Alignment Healthcare is a consumer-centric platform focused on improving healthcare for seniors, primarily through Medicare Advantage Plans.
Alignment healthcare CEO John Kao sells over $6M in shares
John E. Kao, CEO of Alignment Healthcare (NASDAQ: ALHC), sold 298,000 shares worth over $6 million on June 10, 2026, through a pre-arranged trading plan. Despite the stock's recent 28.5% return, InvestingPro analysis indicates it may be overvalued relative to its Fair Value. Kao retains substantial holdings and the company recently surpassed Q1 2026 earnings expectations and announced leadership changes.
Alignment healthcare CEO John Kao sells over $6M in shares By Investing.com
John E. Kao, CEO of Alignment Healthcare (NASDAQ:ALHC), sold 298,000 shares worth over $6 million on June 10, 2026. These sales, executed via a Rule 10b5-1 trading plan established in November 2025, occurred after the stock saw a 28.5% return in the past week but remains overvalued according to InvestingPro analysis. Following the transactions, Kao retains a significant stake of nearly 3 million shares directly and indirectly.
ALHC (ALHC) Form 144 lists 35,951 RSU shares for resale; insider sold 18,404
Alignment Healthcare (ALHC) filed a Form 144 indicating a proposed sale of 35,951 common shares derived from Restricted Stock Units granted on March 13, 2026. The filing also notes a previous sale by Hyong J Kim of 18,404 shares on March 18, 2026, for $328,327.36. This form serves as a regulatory notice of intended resale and not a completed transaction.
Alignment Healthcare (ALHC) EVP Konowiecki sells 25,000 shares under 10b5-1 plan
Joseph S. Konowiecki, EVP of Corporate Affairs and a director at Alignment Healthcare, Inc. (ALHC), sold 25,000 shares of company stock at $21.00 per share on June 11, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. Following the sale, Konowiecki directly holds 1,178,816 shares of Alignment Healthcare common stock.
CEO of Alignment Healthcare (NASDAQ: ALHC) sells 298K shares via trust
John E. Kao, CEO of Alignment Healthcare (ALHC), indirectly sold 298,000 shares of company common stock through the JEK Trust on June 10, 2026. These sales were executed under a Rule 10b5-1 trading plan adopted in November 2025, with weighted-average prices of $20.5962 and $19.6481 per share. Following these transactions, Mr. Kao's indirect holdings via the JEK Trust are 1,609,830 shares and direct holdings are 1,608,743 shares.
Are medical stocks lagging Alignment Healthcare (ALHC) this year?
The article discusses whether medical stocks are underperforming in comparison to Alignment Healthcare (ALHC) this year. It suggests that specific medical stocks might be lagging behind ALHC's performance. The content, however, is not provided beyond the title.
[144] Alignment Healthcare, Inc. SEC Filing
This article details an SEC Form 144 filing by Alignment Healthcare, Inc. (ALHC) for a proposed sale of securities. The filing indicates a sale of 25,000 common shares with an aggregate market value of $525,000, acquired through a stock bonus. The notice was dated June 11, 2026.
Alignment Healthcare (ALHC) Gets a Buy from KeyBanc
KeyBanc analyst Matthew Gillmor maintained a Buy rating on Alignment Healthcare (ALHC) with a $28.00 price target. The company reported a quarterly revenue of $1.24 billion and a net profit of $11.42 million. Despite negative corporate insider sentiment based on increased insider selling, President Mark D. Kent recently bought 14,848 shares.
Alignment Healthcare (ALHC) Gets KeyBanc Backing, 36% PT Hike, Shares Jump
Alignment Healthcare (ALHC) shares surged after KeyBanc initiated an "overweight" rating and a $28 price target, indicating a 37% upside potential. KeyBanc believes that the market's concerns about ALHC are overblown, citing solid fundamentals and an attractive valuation as drivers for recovery, despite the stock lagging behind larger competitors recently. The firm suggests that funds have been flowing into more established players like UnitedHealth Group and Humana, rather than reflecting specific issues with ALHC.
KeyBanc reiterates Overweight on Alignment Healthcare stock at $28 By Investing.com
KeyBanc has reiterated an Overweight rating on Alignment Healthcare (NASDAQ:ALHC) with a $28 price target, despite recent stock volatility attributed to market rotation and concerns over aggressive 2026 guidance and medical loss ratios. The firm believes these bear points are overblown, citing solid fundamentals and an attractive valuation. The company recently exceeded Q1 2026 earnings expectations and announced leadership changes.
Is Alignment Healthcare's (ALHC) Governance Shake-Up Quietly Redefining Its Long-Term Strategic Ambitions?
Alignment Healthcare (ALHC) recently announced that its founder and CEO, John Kao, will also become Chairman, alongside adding senior operational roles and being named to the Fortune 1000 list. This governance shift, combined with new hires, signals a maturing organization focused on formalizing oversight and operational depth as it scales its senior-focused Medicare Advantage model. The article suggests this could impact ALHC's investment narrative and operating outlook, particularly regarding operating leverage, managing complexity, and offsetting reimbursement pressure, although regulatory risks remain.
KeyBanc reiterates Overweight on Alignment Healthcare stock at $28
KeyBanc has reiterated its Overweight rating on Alignment Healthcare (NASDAQ:ALHC) with a price target of $28.00, despite recent stock volatility. The firm attributes the pressure to market rotation and believes that concerns regarding the company's 2026 guidance and medical loss ratio are overblown given moderating utilization,
